# Receptor Recognition by the Novel Coronavirus from Wuhan:an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020). Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of virology, 94(7). DOI: 10.1128/JVI.00127-20.


Maya Paniagua, Drew Cartmel, Christina Dominguez
BIOL 386: Bioinformatics Laboratory
April 16, 2020

#### **Outline**

- 2019-nCoV and SARS-CoV present similarities
- 2019-nCoV is most related to the β-genus lineage b bat SARS-like coronaviruses
- SARS-CoV and 2019-nCoV share sequence similarities in their spike proteins
- SARS-CoV and 2019-nCoV spike proteins are 77% similar
- SARS-CoV contains a core structure as well as a receptor binding motif (RBM)
- Mutations in the RBM spike protein affect binding to the host ACE2 protein
- Amino acid positions that enhance viral binding of SARS-CoV to ACE2
- They built a model of 2019-nCoV binding to ACE2 based off of the previous structure
- Five amino acids in ACE2 that are important for spike protein binding
- Optimal Viral Binding Between Civet SARS-CoV RBD and Civet ACE2
- Model of Viral Binding Between 2019-nCoV RBD and Civet ACE2
- Using the information presented, future work could help researchers make predictions and prepare ways to fight the virus


#### 2019-nCoV has many similarities to SARS-CoV

- 2019-nCoV has many similarities to SARS-CoV including:
  - Belonging to β-genus of coronaviruses
  - O Similar symptoms (Wan, 2020)
- 2019-nCoV causes respiratory illness that is spread through respiratory droplets and has unknown animal origin (CDC, 2020)



(CDC, 2020)

### 2019-nCoV is most related to the β-genus lineage b bat SARS-like coronaviruses



 These other viruses use ACE2 for entry into the cell

# SARS-CoV and 2019-nCoV share sequence similarities in their spike proteins

#### Human-SARS-2002 306 RVVPS GDVVRFPNIT NLCPFGEVFN ATKFPSVYAW ERKKISNCVA DYSVLYNSTF 360 Civet-SARS-2002 306 RVVPS GDVVRFPNIT NLCPFGEVFN ATKFPSVYAW ERKRISNCVA DYSVLYNSTS 360 Bat-SARS-2013 307 RVAPS KEVVRFPNIT NLCPFGEVFN ATTFPSVYAW ERKRISNCVA DYSVLYNSTS 361 2019-nCoV 319 RVOPT ESIVRFPNIT NLCPFGEVFN ATRFASVYAW NRKRISNCVA DYSVLYNSAS 373 Human-SARS-2002 FSTFKCYGVS ATKLNDLCFS NVYADSFVVK GDDVROIAPG OTGVIADYNY KLPDDFMGCV 420 FSTFKCYGVS ATKLNDLCFS NVYADSFVVK GDDVRQIAPG QTGVIADYNY KLPDDFMGCV 420 Civet-SARS-2002 FSTFKCYGVS ATKLNDLCFS NVYADSFVVK GDDVRQIAPG QTGVIADYNY KLPDDFTGCV 421 Bat-SARS-2013 FSTFKCYGVS PTKLNDLCFT NVYADSFVIR GDEVROIAPG OTGKIADYNY KLPDDFTGCV 433 2019-nCoV \*\*\*\*\*\* \*\*\* \*\*\*\*\*\* \*\*\*\*\*\* \*\*\*\*\*\*\* \*\*\* \*\*\* \*\*\* \*\*\* Human-SARS-2002 LAWNTRNIDA TSTGNYNYKY RYLRHGKLRP FERDISNVPF SPDGKPCTP-P ALNCYWPLND 480 Civet-SARS-2002 LAWNTRNIDA TSTGNYNYKY RYLRHGKLRP FERDISNVPF SPDGKPCTP-P ALNCYWPLKD 480 Bat-SARS-2013 LAWNTRNIDA TOTGNYNYKY RSLRHGKLRP FERDISNVPF SPDGKPCTP-P AFNCYWPLND 481 2019-nCoV IAWNSNNLDS KVGGNYNYLY RLFRKSNLKP FERDISTEIY QAGSTPCNGVE GFNCYFPLQS 494 .:\*\*\*:\*\*:. YGFYTTTGIG YOPYRVVVLS FELLNAPATV CGPKL 515 Human-SARS-2002 Civet-SARS-2002 YGFYTTSGIG YQPYRVVVLS FELLNAPATV CGPKL 515 Bat-SARS-2013 YGFYITNGIG YOPYRVVVLS FELLNAPATV CGPKL 516 YGFOPTNGVG YOPYRVVVLS FELLHAPATV CGPKK 529 2019-nCoV

 Suggest the possibility they share the same receptor

### SARS-CoV and 2019-nCoV spike proteins are 77% similar


В

Spike / RBD / RBM	SARS-human	SARS-civet	SARS-bat	2019-nCoV
SARS-human	100% / 100% / 100%			
SARS-civet	98.12% / 98.10% / 97.18%	100% / 100% / 100%		
SARS-bat	92.33% / 94.29% / 92.96%	92.75% / 94.76% / 91.55%	100% / 100% / 100%	
2019-nCoV	76.04% / 73.33% / 50.00%	76.78% / 74.29% / 50.00%	77.50% / 75.71% / 52.78%	100% / 100% / 100%

Spike /RBD /RBM	MERS-human
HKU4-bat	67.04%
	/57.69%
	/40.79%

- MERS and HKU4 have even fewer similarities but share the same receptor
- Sequence similarities strongly suggest SARS-CoV and 2019-nCoV share the same ACE2 receptor

## SARS-CoV contains a core structure as well as a receptor binding motif (RBM)



RBM binds to the human ACE2 receptor


 Does 2019-nCoV bind to ACE2 in the same way?

### Mutations in the RBM spike protein affect binding to the host ACE2 protein

Virus	Year	442	472	479	480	487
SARS - human	2002	Υ	L	N	D	Т
SARS - civet	2002	Y	L	K	D	S
SARS - human/civet	2003	Υ	Р	N	G	S
SARS - civet	2005	Υ	Р	R	G	S
SARS - human	2008	F	F	N	D	S
Viral adaption to human ACE2		F > Y	F > L > P	N = R >>> K	D > G	T >>> S
Optimized - human	In vitro design	F	F	N	D	Т
Viral adaptation to civet ACE2		Y > F	P = L > F	R > K = N	G > D	T>S
Optimized - civet	In vitro design	Y	Р	R	G	Т
SARS - bat	2013	S	F	N	D	N
2019-nCoV – human	2019	L (455)	F (486)	Q (493)	S (494)	N (501)

- Each amino acid number on the top row represents a different residue
- Red coloring indicates the differences


#### Amino acid positions that enhance viral binding of SARS-CoV to ACE2



Human SARS-CoV-optimized RBD

- Receptor binding motif of Human SARS-Cov (magenta) binding to Human ACE2 (green)
- Specific amino acids at the 442, 472, 479, 480, and 487 positions enhance viral binding to ACE2
- When an RBD contains all of these residues, it will bind with high affinity allowing for the virus to enter human cells with high efficiency

### They built a model of 2019-nCoV binding to ACE2 based off of the previous structure



- Receptor binding motif of Human 2019-nCoV (magenta) binding to Human ACE2 (green)
- Specific amino acids at the positions 455, 486, 493, 494, and 501 enhance the viral binding to ACE2


### Five amino acids in ACE2 that are important for spike protein binding

Α

ACE2	31	35	38	82	353
Human	K	E	D	М	K
Civet	Т	E	E	Т	K
Bat	K	K	D	N	K
Mouse	N	E	D	S	Н
Rat	K	E	D	N	Н
Pig	K	E	D	Т	K
Ferret	K	E	Е	Т	K
Cat	K	E	Е	Т	K
Orangutan	K	E	D	М	K
Monkey	K	E	D	М	K

 It is predicted that it would bind to all of these species except mice and rat

#### Optimal Viral Binding Between Civet SARS-CoV RBD and Civet ACE2



- Glu35 to Arg 479 is an ionic bond
- E38 to K353 is an ionic bond
- T31 to Y442 is a hydrogen bond
- Unfavorable interactions do not occur

#### Model of Viral Binding Between 2019-nCoV RBD and Civet ACE2

Civet ACE2 F486 Q493

- Unfavorable interactions occur
- 2019-nCoV has not adapted to binding efficiently to ACE2
- But ACE2 is still likely used

(Wan, 2020)

Human 2019-nCoV RBD (model)

#### **Discussion**

- 2019-nCoV shares sequence, structural, and binding similarities with SARS-CoV
- The authors used the same predictive framework to study 2019-nCoV as they did with SARS-CoV in 2003
- The main limitation of this study was that the authors do not actually know the structure yet
- Using the information presented, future work could help researchers make predictions and prepare ways to fight the virus

#### Summary

- 2019-nCoV and SARS-CoV present similarities
- 2019-nCoV is most related to the β-genus lineage b bat SARS-like coronaviruses
- SARS-CoV and 2019-nCoV share sequence similarities in their spike proteins
- SARS-CoV and 2019-nCoV spike proteins are 77% similar
- SARS-CoV contains a core structure as well as a receptor binding motif (RBM)
- Mutations in the RBM spike protein affect binding to the host ACE2 protein
- Amino acid positions that enhance viral binding of SARS-CoV to ACE2
- They built a model of 2019-nCoV binding to ACE2 based off of the previous structure
- Five amino acids in ACE2 that are important for spike protein binding
- Optimal Viral Binding Between Civet SARS-CoV RBD and Civet ACE2
- Model of Viral Binding Between 2019-nCoV RBD and Civet ACE2
- Using the information presented, future work could help researchers make predictions and prepare ways to fight the virus

#### References

CDC. (2020). Know the facts about coronavirus disease 2019. Center for Disease Control.https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/share-facts.ht ml.

Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020). Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of virology, 94(7). DOI: 10.1128/JVI.00127-20.

Thank you to Dr. Dahlquist, Loyola

**Marymount University Biology Department,** 

and the BIOL 368 class!